Announcement by Sumitomo Pharma America, Inc. (SMPA) Regarding the U.S. Orphan Drug Designation for an Allogeneic iPS cell-derived Retinal Sheet (3-dimensional retina) as a Treatment for Retinitis Pigmentosa
SMPA announced on 23 March 2026 that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to an investigational allogeneic iPS cell-derived retinal sheet (3-dimensional retina, development code: DSP-3077) for the treatment of retinitis pigmentosa.
Link
